Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
GLP-1 demand is going to remain higher than supply for foreseeable future, says BMO's Evan Seigerman
05:59pm, Tuesday, 24'th Sep 2024
Evan Seigerman, BMO senior analyst, joins 'Closing Bell Overtime' to talk today's Capitol Hill hearing with Novo Nordisk's CEO and the demand for weight-loss drugs.
Healthy Returns: Weight loss drug Wegovy could face Medicare price negotiations next
01:52pm, Tuesday, 24'th Sep 2024
Novo Nordisk's weight loss drug Wegovy could face Medicare price negotiations next. Meanwhile, Particle Health files an antitrust suit against Epic Systems.
Novo Nordisk CEO testifies before Senate on weight loss drug prices
11:36am, Tuesday, 24'th Sep 2024
CNBC's Angelica Peebles reports on Novo Nordisk's testimony before the Senate Health, Education, Labor, and Pensions Committee.
Novo Nordisk's Setback Won't Last: A Game-Changing Drug Emerges
09:54am, Tuesday, 24'th Sep 2024
Novo Nordisk NYSE: NVO took a hit on its stock price last week after it received bad news on one of its in-development treatments. At the same time, shares of big and small competitors rallied as a re
Novo Nordisk CEO set to defend Ozempic, Wegovy prices on Capitol Hill
09:01am, Tuesday, 24'th Sep 2024
The CEO of Novo Nordisk is set to face pointed questions on Capitol Hill Tuesday about the prices of the Danish pharmaceutical giant's blockbuster drugs Ozempic and Wegovy.
Novo Nordisk CEO to testify at Senate hearing over high weight loss drug prices
07:00am, Tuesday, 24'th Sep 2024
Novo Nordisk's top executive is slated to face a Senate grilling over the high prices of the company's weight loss drug Wegovy and diabetes treatment Ozempic. The Danish drugmaker's CEO, Lars Fruergaa
Novo Nordisk CEO faces US Congress scrutiny over weight-loss drug pricing
06:08am, Tuesday, 24'th Sep 2024
U.S. Senator Bernie Sanders is set to question Novo Nordisk CEO Lars Jorgensen on Tuesday over the drugmaker's prices for its popular weight-loss and diabetes medicines that can cost Americans more th
2 Weight-Loss Stocks That Could Rocket Higher This Year
04:57am, Tuesday, 24'th Sep 2024
Injections that help folks manage their appetite already generate over $45 billion in annual revenue. Total sales of weight-management drugs are expected to reach $100 billion annually by 2030.
Novo says Ozempic to be eligible for US price negotiations in less than a year
06:13pm, Monday, 23'rd Sep 2024
Novo Nordisk's blockbuster diabetes drug Ozempic will be eligible for U.S. government's price negotiations in less than a year based on current criteria, the Danish drugmaker's CEO Lars Fruergaard Jor
Novo Nordisk Stock Slips as CEO Faces Senate Inquiry Into Wegovy, Ozempic Prices
02:40pm, Monday, 23'rd Sep 2024
Novo Nordisk's (NVO) U.S.-listed shares lost ground Monday, a day before a Senate hearing on the costs of the company's popular weight-loss drugs Wegovy and Ozempic.
Novo Nordisk CEO To Face Senate Scrutiny Over High Ozempic And Wegovy Prices, Hearing Scheduled On Tuesday
01:11pm, Monday, 23'rd Sep 2024
Lars Fruergaard Jørgensen, President and CEO of Novo Nordisk A/S NVO, is set to face tough questions from the U.S. lawmakers regarding the steep prices of the company's diabetes and weight-loss drugs
NVO Stock Down on Unsatisfactory Data From Mid-Stage Obesity Study
12:21pm, Monday, 23'rd Sep 2024
Novo Nordisk stock falls 5.5% on unsatisfactory safety and efficacy data from a mid-stage study of investigational obesity candidate, monlunabant.
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
10:06am, Monday, 23'rd Sep 2024
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Novo Nordisk A/S - share repurchase programme
07:56am, Monday, 23'rd Sep 2024
Bagsværd, Denmark, 23 September 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Co
Novo Nordisk faces US congressional grilling over price of weight loss drugs, FT reports
12:14am, Monday, 23'rd Sep 2024
Novo Nordisk's chief executive is preparing for a showdown next week with U.S. Senator Bernie Sanders over the high price of blockbuster diabetes and weight loss drugs, as Ozempic falls into the scope
